Free press releases distribution network?

Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Peter Palese to Keynote at Influenza Research & Development Meeting, July 9-10, San Francisco, California - Peter Palese, Professor and Chair, Department of Microbiology, Mount Sinai School of Medicine, will be giving a keynote presentation entitled “A Universal Influenza Virus Vaccine” at the Influenza Research and Development Conference on July 9th-10th - GTC
Peter Palese to Keynote at Influenza Research & Development Meeting, July 9-10, San Francisco, California

 

PRZOOM - /newswire/ - Monrovia, CA, United States, 2012/06/12 - Peter Palese, Professor and Chair, Department of Microbiology, Mount Sinai School of Medicine, will be giving a keynote presentation entitled “A Universal Influenza Virus Vaccine” at the Influenza Research and Development Conference on July 9th-10th - GTC.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Influenza virus infection continues to be a major public health problem worldwide. Available influenza virus vaccines are effective in healthy individuals but are usually re-formulated annually due to antigenic drift of the circulating viruses. Thus, influenza vaccination programs requiring yearly reimmunization are both expensive and difficult to implement. Recent reports on broadly neutralizing anti-influenza hemagglutinin antibodies suggest that eliciting broad-spectrum humoral immunity against influenza viruses should be possible, given the right immunogen.
Most broadly neutralizing anti-influenza hemagglutinin antibodies bind to the conserved but immuno-subdominant stalk region of the hemagglutinin molecule. Such stalk-specific antibodies directed against the sub-dominant domain of the hemagglutinin have also been found responsible for the extinction of the seasonal H1N1 influenza viruses after the pandemic H1N1 viruses appeared in 2009. In order to induce such antibodies via vaccination, we have designed different hemagglutinin-based immunogens.

These novel constructs (for example, headless hemagglutinins, chimeric hemagglutinins) direct the immune response against the stalk domain efficiently boosting a cross-reactive immune response. Preliminary data from heterologous virus challenge experiments in mice suggest that these novel vaccine constructs are able to induce high levels of broadly neutralizing antibodies that protect against morbidity and mortality. The development of a universal influenza virus vaccine, that - similar to the existing polio and measles vaccines - requires a single or only a few immunizations represents a major advance towards the control of influenza worldwide.

Benefits of this talk include:

1) Chimeric Influenza Viruses as analytical tools;
2) Extinction of seasonal influenza viruses by pandemic strains;
3) Hemagglutinin stem antibodies;
4) Heterosubtypic protection.

Dr. Palese is Professor of Microbiology and Chair of the Department of Microbiology at the Mount Sinai School of Medicine in New York. He established the first genetic maps for influenza A, B and C viruses, identified the function of several viral genes, and defined the mechanism of neuraminidase inhibitors (which are now FDA-approved antivirals). Dr. Palese also pioneered the field of reverse genetics for negative strand RNA viruses, which allows the introduction of site-specific mutations into the genomes of these viruses. This technique is crucial for the study of the structure/function relationships of viral genes, for investigation of viral pathogenicity and for development and manufacture of novel vaccines. Dr. Palese was elected to the National Academy of Sciences in 2000 for his seminal studies on influenza viruses.

GTC’s Influenza Research & Development is a two-day conference that will be held at the San Francisco Airport Marriott Waterfront. This conference will cover various aspects of basic research in influenza including correlates of protection, the role of t-cells in influenza, antibodies, adjuvants and vaccination. Topics such as the current threat of the H5N1 virus and updates on the universal influenza vaccine will be covered by key academic researchers and leaders of the industry. Additionally, government representatives from BARDA, FDA and the USAID will discuss regulatory and government policies for vaccinations in conjunction with our 10th Vaccines Research and Development: All Things Considered Conference.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Peter Palese to Keynote at Influenza Research & Development Meeting, July 9-10, San Francisco, California

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: GTCbio.com 
626-256-6405 ken.lin[.]gtcbio.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  MagLar, Inc.

Visit  JobsWare.com

Visit  BizJobs.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today